Background: 1-3, 1-6 β-glucan derived from Baker’s yeast (Saccharomyces cerevisiae) has been widely studied for its immune stimulatory capabilities and safety. Previous studies found β-glucan to have efficacy at re...Background: 1-3, 1-6 β-glucan derived from Baker’s yeast (Saccharomyces cerevisiae) has been widely studied for its immune stimulatory capabilities and safety. Previous studies found β-glucan to have efficacy at reducing incidence of URTIs as well as being a low risk for negative side effects. The current study aimed to examine the effects of yeast β-glucan (Angel Yeast) on cold and flu incidences and symptoms in healthy adults. Methods: Two hundred and thirty-one males and females aged 18 to 65 years old supplemented with either β-glucan or a placebo for 3-months. Participants completed a general health questionnaire every 4 weeks and in addition, if participants experienced any cold or flu symptoms, these were recorded daily (along with severity) until resolved or up to 2 weeks. Results: Supplementation with β-glucan reduced the self-reported severity of sore throats and improved sleep quality compared to the placebo group. Conclusions: Yeast β-glucan supplementation appears to be able to help reduce certain symptoms experienced during a cold or flu episode and is safe and well tolerated.展开更多
Background and Aims:Irreversible electroporation(IRE)is an emerging local ablation therapy which may be effective for unresectable tumors.This study aimed to evaluate the safety and efficacy of percutaneous IRE in the...Background and Aims:Irreversible electroporation(IRE)is an emerging local ablation therapy which may be effective for unresectable tumors.This study aimed to evaluate the safety and efficacy of percutaneous IRE in the treatment of hepatocellular carcinoma(HCC)abutting the diaphragm.Methods:A total of 26 participants with 39 tumors abutting the diaphragm were prospectively evaluated between July 2015 and September 2018.Complications associated with IRE were recorded,and the survival benefit of IRE was analyzed.The factors associated with time to local tumor progression(LTP)were analyzed using univariate and multivariate Cox regression models.Results:No major complications or treatmentrelated deaths occurred.The technical success rate was 96.2%(25/26)and complete ablation rate was 92.3%(36/39).The median followup period was 16.7 months(range:3.0-43.0 months),the LTP occurred in 15.2%of tumors and median time to LTP was 20.4 months.Overall,tumor size(hazard ratio:1.24[95%confidence interval:0.38,3.81],p=0.03)was the only factor associated with time to LTP.Conclusions:This study shows for the first time that percutaneous IRE is a safe and effective ablation technology for HCC abutting the diaphragm.展开更多
文摘Background: 1-3, 1-6 β-glucan derived from Baker’s yeast (Saccharomyces cerevisiae) has been widely studied for its immune stimulatory capabilities and safety. Previous studies found β-glucan to have efficacy at reducing incidence of URTIs as well as being a low risk for negative side effects. The current study aimed to examine the effects of yeast β-glucan (Angel Yeast) on cold and flu incidences and symptoms in healthy adults. Methods: Two hundred and thirty-one males and females aged 18 to 65 years old supplemented with either β-glucan or a placebo for 3-months. Participants completed a general health questionnaire every 4 weeks and in addition, if participants experienced any cold or flu symptoms, these were recorded daily (along with severity) until resolved or up to 2 weeks. Results: Supplementation with β-glucan reduced the self-reported severity of sore throats and improved sleep quality compared to the placebo group. Conclusions: Yeast β-glucan supplementation appears to be able to help reduce certain symptoms experienced during a cold or flu episode and is safe and well tolerated.
基金This research is funded by National Natural Science Foundation of China under Project no. 61210013, Science and Technology Planning Project of Guangdong Province under no. 2014A020215027.
基金supported by grants from the International Science Foundation of Affiliated Fuda Cancer Hospital,Jinan University(No.Y2018-ZD-01).
文摘Background and Aims:Irreversible electroporation(IRE)is an emerging local ablation therapy which may be effective for unresectable tumors.This study aimed to evaluate the safety and efficacy of percutaneous IRE in the treatment of hepatocellular carcinoma(HCC)abutting the diaphragm.Methods:A total of 26 participants with 39 tumors abutting the diaphragm were prospectively evaluated between July 2015 and September 2018.Complications associated with IRE were recorded,and the survival benefit of IRE was analyzed.The factors associated with time to local tumor progression(LTP)were analyzed using univariate and multivariate Cox regression models.Results:No major complications or treatmentrelated deaths occurred.The technical success rate was 96.2%(25/26)and complete ablation rate was 92.3%(36/39).The median followup period was 16.7 months(range:3.0-43.0 months),the LTP occurred in 15.2%of tumors and median time to LTP was 20.4 months.Overall,tumor size(hazard ratio:1.24[95%confidence interval:0.38,3.81],p=0.03)was the only factor associated with time to LTP.Conclusions:This study shows for the first time that percutaneous IRE is a safe and effective ablation technology for HCC abutting the diaphragm.
